– Moderna wants to strengthen its collaboration with Switzerland
As with Australia and Canada, the company would like to enter into a partnership with the Confederation. Negotiations are also underway about a vaccination subscription.
Posted today at 10:42 a.m.
- Advertisement -
Vaccine producer Moderna wants to deepen its collaboration with Switzerland. Negotiations are underway in particular on a vaccination subscription with a commitment to purchase a certain volume by Switzerland, said Tuesday the boss of the American biotechnology company Stéphane Bancel.
- Advertisement -
Moderna is in almost weekly contact with the Confederation. The company is discussing a partnership with Switzerland, as it has already done similarly with Australia and Canada, said Stéphane Bancel in an interview with Tamedia titles.
A vaccination subscription
“We have started negotiations with Switzerland for a vaccination subscription. We also want to invest in scientists in Switzerland and develop vaccines there in hospital and university laboratories, ”explains Stéphane Bancel, the French boss of the American company. Moderna also wants to carry out more clinical trials in Switzerland.
The boss of Moderna would like to enter into a long-term partnership with Switzerland, with a commitment to purchase a certain volume. This would allow rapid delivery, even in the event of a new virus. It could be a partnership between Moderna, Lonza and the Confederation. “But it is still too early to give details,” notes Stéphane Bancel.
A series of new vaccines
A series of mRNA vaccines are in development, for example against influenza or RS viruses, which cause fatal respiratory illness in the elderly and young children. “We could combine these three mRNA vaccines into a single dose and offer governments to secure deliveries for a given quantity over several years.”
In the event of a new pandemic, Moderna could very quickly develop a new vaccine. A country which would have ensured regular quantities would then be delivered as a priority.
In some countries, which become partners, the American biotechnology company sets up a production unit in return. In Switzerland, the model is different due to the partnership with Lonza.
Moderna is also working on a suitable vaccine, the development of which would take around 90 days, or even less. However, the question arises as to whether approval authorities such as Swissmedic will again require a study for this suitable vaccine, which would take three additional months. “In the end, it could take up to six months before we have an Omicron vaccine.”
But for now, people vaccinated against the coronavirus in Switzerland should quickly receive a booster dose, advises Stéphane Bancel. They would thus be well protected against hospitalization and severe disease progression after infection with the Omicron variant.